Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin

Diabetes/Metabolism Research and Reviews

Volumn 22, Issue 6, 2006, Pages 477-482

  Monami, Matteo ^a   Luzzi, Chiara ^a   Lamanna, Caterina ^a   Chiasserini, Veronica ^a   Addante, Filomena ^a   Desideri, Carla Maria ^a   Masotti, Giulio ^a   Marchionni, Niccolò ^a   Mannucci, Edoardo ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Diabetes mellitus; Insulin secretagogues; Metformin; Mortality

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; CHLORPROPAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INSULIN SECRETAGOGUE; METFORMIN; PHENFORMIN; REPAGLINIDE; SULFONYLUREA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BODY MASS; COHORT ANALYSIS; COMORBIDITY; CONFIDENCE INTERVAL; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE REGISTRY; DOSE RESPONSE; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; INSULIN TREATMENT; ITALY; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; SCORING SYSTEM;

AGED; CARBAMATES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DRUG COMBINATIONS; FEMALE; GLICLAZIDE; GLYBURIDE; HUMANS; INSULIN; ITALY; MALE; METFORMIN; MIDDLE AGED; PIPERIDINES;

EID: 33751184340     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.642     Document Type: Article

References (21)

1. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352(9131): 854-865.
2. Fisman EZ, Tenenbaum A, Boyko V, et al. Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up. Clin Cardiol 2001; 24(2): 151-158.
3. Mannucci E, Monami M, Masotti G, Marchionni N. All-cause mortality in diabetic patients treated with combinations of sulfonylureas and biguanides. Diabetes Metab Res Rev 2004; 20(1): 44-47.
4. Olsson J, Lindberg G, Gottsater M, et al. Increased mortality in type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study. Diabetologia 2000; 43(5): 558-560.
5. Gulliford M, Latinovic R. Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study. Diabetes Metab Res Rev 2004; 20(3): 239-245.
6. Johnson JA, Simpson SH, Toth EL, Majumdar SR. Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with type 2 diabetes. Diabet Med 2005; 22(4): 497-502.
7. Report of the expert committee on the diagnosis and classification of diabetes mellitus Diabetes Care 1997; 20(7): 1183-1197.
8. Chalmers J, MacMahon S, Mancia G, et al. WHO-International society of hypertension guidelines for the management of hypertension. Guidelines sub-committee of the WHO. Clin Exp Hypertens 1999; 21: 1009-1060.
9. Blackburn H. Classification of the elettrocardiogram for population studies: Minnesota Code. J Electrocardiol 1969; 2: 305-310.
10. Charlson M, Szatrowski T, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidenziol 1994; 47: 1245-1251.
11. Mocanu MM, Maddock HL, Baxter GF, et al. Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation 2001; 103(25): 3111-3116.
12. Klepzig H, Kober G, Matter C, et al. Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J 1999; 20(6): 439-446.
13. Ovunc K. Effects of glibenclamide, a K(ATP) channel blocker, on warm-up phenomenon in type II diabetic patients with chronic stable angina pectoris. Clin Cardiol 2000; 23(7): 535-539.
14. Scognamiglio R, Avogaro A, Vigili D, et al. Effects of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardial dysfunction in type 2 diabetes. Diabetes 2002; 51(3): 808-812.
15. Jollis J, Simpson R, Cascio W, et al. Relation between sulfonylurea therapy, complications, and outcome for elderly patients with acute myocardial infarction. Am Heart J 1999; 138: S376-S380.
16. Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 2005; 28(10): 2345-2351.
17. Gribble FM, Ashcroft FM. Differential sensitivity of beta-cell and extrapancreatic K(ATP) channels to gliclazide. Diabetologia 1999; 42(7): 845-848.
18. Wolffenbuttel BH. Repaglinide-a new compound for the treatment of patients with type 2 diabetes. Neth J Med 1999; 55(5): 229-234.
19. Quast U, Stephan D, Bieger S, Russ U. The impact of ATP-sensitive K+ channel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardium. Diabetes 2004; 53(Suppl. 3): S156-S164.
20. Decode study group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE Study Group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis of Diagnostic criteria in Europe. Lancet 1999; 354(9179): 617-621.
21. Garber AJ, Donovan DS, Dandona P, Bruce S, Park JS. Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. J Clin Endocr Metab 2003; 88(8): 3598-3604.